|
|
 Previous Article | Table of Contents | Next Article 
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in
human leukemia cells
SH Kaufmann, PA Svingen, SD Gore, DK Armstrong, YC Cheng and EK Rowinsky
Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Topotecan (TPT) is a topoisomerase I (topo I) poison that has shown
promising antineoplastic activity in solid tumors and acute leukemia. In
the present study, a band depletion assay was used to evaluate the ability
of TPT to stabilize topo I-DNA adducts in human leukemia cell lines and in
clinical leukemia samples ex vivo. This assay showed that 50% of the
cellular topo I in HL-60 human myelomonocytic leukemia cells became
covalently bound to DNA at an extracellular TPT concentration of 4
micromol/L. In contrast, in 13 clinical specimens of human leukemia
harvested before treatment of patients with TPT, the TPT concentration
required to stabilize 50% of the cellular topo I in topo I-DNA complexes
ranged from 3 to greater than 100 micromol/L (median, 30 micromol/ L). Flow
microfluorimetry showed that cellular TPT accumulation varied over only a
twofold range and failed to provide evidence for transport-mediated
resistance in the clinical samples. These observations raise the
possibility that formation of topo I-DNA adducts is diminished in many
specimens of refractory/relapsed acute leukemia by a mechanism that might
alter topo I sensitivity to TPT.
Volume 89,
Issue 6,
pp. 2098-2104,
03/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. E. Wahner Hendrickson, P. Haluska, P. A. Schneider, D. A. Loegering, K. L. Peterson, R. Attar, B. D. Smith, C. Erlichman, M. Gottardis, J. E. Karp, et al.
Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro
Cancer Res.,
October 1, 2009;
69(19):
7635 - 7643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. S. Flatten, S. L. Safgren, J. M. Wagner, M. M. Ames, L. M. Karnitz, and S. H. Kaufmann
Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines
Mol. Pharmacol.,
September 1, 2008;
74(3):
724 - 735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Hackbarth, M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. L. Peterson, X. W. Meng, L. M. Karnitz, and S. H. Kaufmann
Mitotic Phosphorylation Stimulates DNA Relaxation Activity of Human Topoisomerase I
J. Biol. Chem.,
June 13, 2008;
283(24):
16711 - 16722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. W. Meng, S.-H. Lee, H. Dai, D. Loegering, C. Yu, K. Flatten, P. Schneider, N. T. Dai, S. K. Kumar, B. D. Smith, et al.
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis: A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION
J. Biol. Chem.,
October 12, 2007;
282(41):
29831 - 29846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Arakawa, H. Suzuki, S. Saito, and H. Yamada
Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Mol. Cancer Ther.,
March 1, 2006;
5(3):
502 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kaufmann, J. E. Karp, L. Letendre, T. J. Kottke, S. Safgren, J. Greer, I. Gojo, P. Atherton, P. A. Svingen, D. A. Loegering, et al.
Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia
Clin. Cancer Res.,
September 15, 2005;
11(18):
6641 - 6649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig, S. M. Geyer, I. Ghobrial, D. J. Inwards, R. Fonseca, P. Kurtin, S. M. Ansell, R. Luyun, P. J. Flynn, R. F. Morton, et al.
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
J. Clin. Oncol.,
August 10, 2005;
23(23):
5347 - 5356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Bruzek, J. N. Poynter, S. H. Kaufmann, and A. A. Adjei
Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336)
Mol. Pharmacol.,
August 1, 2005;
68(2):
477 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood,
July 1, 2005;
106(1):
318 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Flatten, N. T. Dai, B. T. Vroman, D. Loegering, C. Erlichman, L. M. Karnitz, and S. H. Kaufmann
The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons
J. Biol. Chem.,
April 8, 2005;
280(14):
14349 - 14355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chandra, J. Hackbarth, S. Le, D. Loegering, N. Bone, L. M. Bruzek, V. L. Narayanan, A. A. Adjei, N. E. Kay, A. Tefferi, et al.
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
Blood,
December 15, 2003;
102(13):
4512 - 4519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. W. Meng, J. Chandra, D. Loegering, K. Van Becelaere, T. J. Kottke, S. D. Gore, J. E. Karp, J. Sebolt-Leopold, and S. H. Kaufmann
Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro
J. Biol. Chem.,
November 21, 2003;
278(47):
47326 - 47339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Adjei, A. Mauer, L. Bruzek, R. S. Marks, S. Hillman, S. Geyer, L. J. Hanson, J. J. Wright, C. Erlichman, S. H. Kaufmann, et al.
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
May 1, 2003;
21(9):
1760 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. F. Mow, J. Chandra, P. A. Svingen, C. G. Hallgren, E. Weisberg, T. J. Kottke, V. L. Narayanan, M. R. Litzow, J. D. Griffin, E. A. Sausville, et al.
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
Blood,
January 15, 2002;
99(2):
664 - 671.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood,
June 1, 2001;
97(11):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al.
The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux
Cancer Res.,
January 1, 2001;
61(2):
739 - 748.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Nakashio, N. Fujita, S. Rokudai, S. Sato, and T. Tsuruo
Prevention of Phosphatidylinositol 3'-Kinase-Akt Survival Signaling Pathway during Topotecan-induced Apoptosis
Cancer Res.,
September 1, 2000;
60(18):
5303 - 5309.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. A. Adjei, J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann
Comparison of Potential Markers of Farnesyltransferase Inhibition
Clin. Cancer Res.,
June 1, 2000;
6(6):
2318 - 2325.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. C. Bible, R. H. Bible Jr., T. J. Kottke, P. A. Svingen, K. Xu, Y.-P. Pang, E. Hajdu, and S. H. Kaufmann
Flavopiridol Binds to Duplex DNA
Cancer Res.,
May 1, 2000;
60(9):
2419 - 2428.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. A. Adjei, C. Erlichman, J. N. Davis, D. L. Cutler, J. A. Sloan, R. S. Marks, L. J. Hanson, P. A. Svingen, P. Atherton, W. R. Bishop, et al.
A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity
Cancer Res.,
April 1, 2000;
60(7):
1871 - 1877.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. C. Bible, S. A. Boerner, K. Kirkland, K. L. Anderl, D. Bartelt Jr., P. A. Svingen, T. J. Kottke, Y. K. Lee, S. Eckdahl, P. G. Stalboerger, et al.
Characterization of an Ovarian Carcinoma Cell Line Resistant to Cisplatin and Flavopiridol
Clin. Cancer Res.,
February 1, 2000;
6(2):
661 - 670.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Samejima, P. A. Svingen, G. S. Basi, T. Kottke, P. W. Mesner Jr., L. Stewart, F. Durrieu, G. G. Poirier, E. S. Alnemri, J. J. Champoux, et al.
Caspase-mediated Cleavage of DNA Topoisomerase I at Unconventional Sites during Apoptosis
J. Biol. Chem.,
February 12, 1999;
274(7):
4335 - 4340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Winter and M. Weller
Potentiation of CD95L-Induced Apoptosis of Human Malignant Glioma Cells by Topotecan Involves Inhibition of RNA Synthesis but Not Changes in CD95 or CD95L Protein Expression
J. Pharmacol. Exp. Ther.,
September 1, 1998;
286(3):
1374 - 1382.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. Relias and J. Andrew Skirvin
Review : Topoisomerase I inhibitors: 1. Topotecan
Journal of Oncology Pharmacy Practice,
December 1, 1997;
3(4):
173 - 185.
[Abstract]
[PDF]
|
|
|
|
|
